GlassScriptPhysician profile
Aria Sherazee
NPI 1326724352
$4,662.82
in general payments reported to CMS, 2019-2025
38 companies · $177 in 2025
The $177 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,569 · 2024: $2,917 · 2025: $177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,663.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,662.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $530.60 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $376.77 | 2023-2024 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $372.86 | 2023-2024 | Austedo Xr, Ajovy |
| Pfizer INC. | $337.53 | 2023-2025 | |
| Boston Scientific Corporation | $327.09 | 2023-2024 | |
| Ucb, INC. | $299.62 | 2024 | Rystiggo, Zilbrysq, Briviact |
| Takeda Pharmaceuticals U.S.A., INC. | $234.31 | 2023-2024 | Hyqvia, Trintellix |
| Eisai INC. | $214.43 | 2023-2024 | |
| Lilly USA, LLC | $194.65 | 2023-2024 | Amyvid, Kisunla, Emgality |
| Otsuka America Pharmaceutical, INC. | $191.37 | 2023-2024 | Rexulti, Nuedexta |
| Mdd US Operations, LLC | $182.38 | 2023-2024 | Gocovri, Gocovri |
| Harmony Biosciences LLC | $156.97 | 2023-2024 | Wakix |
| Jazz Pharmaceuticals INC. | $146.98 | 2023-2024 | Epidiolex |
| Novartis Pharmaceuticals Corporation | $123.40 | 2023-2024 | |
| Supernus Pharmaceuticals, INC. | $121.23 | 2024 | Qelbree |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $113.07 | 2023-2024 | |
| Tanabe Pharma America, INC. | $74.01 | 2024 | |
| Biogen, INC. | $64.38 | 2024 | Vumerity, Tysabri |
| Amneal Pharmaceuticals LLC | $54.28 | 2024 | Rytary |
| Lundbeck LLC | $53.34 | 2023-2024 | Rexulti, Vyepti |
| Acadia Pharmaceuticals INC | $42.60 | 2023-2024 | Nuplazid |
| Argenx US, INC. | $42.44 | 2023-2024 | Vyvgart, Vyvgart Hytrulo |
| Celgene Corporation | $41.96 | 2024 | Zeposia |
| Acorda Therapeutics, INC | $38.88 | 2023 | Ampyra, Inbrija |
| Insightec,INC | $33.87 | 2024-2025 | Exablate |
| E.R. Squibb & Sons, L.L.C. | $32.69 | 2023 | Zeposia |
| Alexion Pharmaceuticals, INC. | $32.14 | 2024 | Ultomiris |
| Livanova USA, INC. | $28.45 | 2024 | Vns Therapy Sentiva Model 1000 Generator |
| Genentech USA, INC. | $28.28 | 2023-2024 | Ocrevus, Ocrevus Zunovo |
| Csl Behring | $24.19 | 2024 | Hizentra |
| Merz Pharmaceuticals, LLC | $21.85 | 2023 | Xeomin |
| Idorsia Pharmaceuticals US INC | $20.68 | 2023 | Quviviq |
| Neurelis, INC. | $20.23 | 2023 | Valtoco |
| Ge Healthcare | $19.21 | 2025 | |
| Inspire Medical Systems, INC. | $18.84 | 2024 | Inspire |
| Emd Serono, INC. | $18.60 | 2023 | Mavenclad |
| Azurity Pharmaceuticals, INC. | $14.83 | 2024 | |
| Sumitomo Pharma America, INC. | $13.81 | 2024 | Aptiom |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aria Sherazee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.